An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
NCT ID: NCT03351231
Last Updated: 2020-08-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
7 participants
INTERVENTIONAL
2017-11-27
2018-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
NCT03400332
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
NCT03661632
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
NCT03994601
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
NCT03369223
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
BMS-986242 administered in combination with Nivolumab
BMS-986242
Specified dose on specified days
Nivolumab
Specified dose on specified days
Dose Expansion
BMS-986242 administered in combination with Nivolumab
BMS-986242
Specified dose on specified days
Nivolumab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986242
Specified dose on specified days
Nivolumab
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* Ability to swallow tablets
* Adequate bone marrow and organ function, as defined by the protocol
Exclusion Criteria
* Ocular melanoma
* Any significant acute or chronic medical illness
* Prior malignancy
* Other active malignancy requiring concurrent intervention
* Prior organ allograft or allogeneic bone marrow transplantation
* Participants with active, known, or suspected autoimmune disease
* Requirement for daily supplemental oxygen
* Uncontrolled or significant cardiovascular disease
* Pre-existing liver disease
* Gastrointestinal disease known to interfere with absorption
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Alabama At Birmingham
Birmingham, Alabama, United States
Hoag Memorial Hospital Presbyterian
Los Angeles, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Local Institution
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-003603-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CA024-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.